Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Kissei Pharmaceutical Co ( (JP:4547) ).
Kissei Pharmaceutical Co., Ltd. and Ferring Pharma Co., Ltd. have announced the termination of their co-promotion agreement for Minirin Melt and Desmopressin formulations in Japan, effective March 31, 2025. After this date, Ferring will assume sole responsibility for the promotion of these drugs, impacting Kissei’s operations in the related therapeutic areas.
More about Kissei Pharmaceutical Co
Kissei Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company focused on providing innovative pharmaceuticals in the fields of urology, nephrology/dialysis, gynecology, and rare/intractable diseases. It operates with a strong R&D orientation and aims to contribute to society through high-quality pharmaceutical products.
YTD Price Performance: -1.34%
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $1.1B
For a thorough assessment of 4547 stock, go to TipRanks’ Stock Analysis page.